...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZEN-3694 Single Agent Trial Status
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Yes, I think the Zenith data looks very promising and I am optimistic of more good news coming out between now and year's end.

A better BET than RVX? I like 'em both. Double down!

BearDownAZ

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply